Empowered Funds LLC trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 35.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 54,188 shares of the company’s stock after selling 30,187 shares during the quarter. Empowered Funds LLC’s holdings in Novo Nordisk A/S were worth $1,991,000 at the end of the most recent reporting period.
Other institutional investors also recently added to or reduced their stakes in the company. Godfrey Financial Associates Inc. bought a new position in Novo Nordisk A/S in the 4th quarter worth about $25,000. Scarborough Advisors LLC purchased a new position in Novo Nordisk A/S during the 1st quarter worth $26,000. WealthCollab LLC raised its holdings in shares of Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after acquiring an additional 260 shares in the last quarter. Maseco LLP bought a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at about $29,000. Finally, Jackson Grant Investment Advisers Inc. purchased a new stake in Novo Nordisk A/S during the fourth quarter worth $29,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.
Trending Headlines about Novo Nordisk A/S
Here are the key news stories impacting Novo Nordisk A/S this week:
- Positive Sentiment: Strong quarterly results and raised outlook: Novo Nordisk beat second-quarter revenue expectations by approximately 10% and adjusted EPS estimates by more than 20%. Revenue increased 7% year over year, operating profit rose 11%, and management lifted its 2026 sales and profit outlook for the second time this year. Novo Nordisk: The Market Has Lost Its Mind, Too Cheap To Ignore
- Positive Sentiment: Continued GLP-1 demand: International markets and obesity care continued to drive growth, while accelerating demand for the Wegovy pill supported the improved outlook. The company also retains substantial profitability and cash generation to fund research, development and shareholder returns. NVO Q2 Earnings Call Centers on Wegovy Pill and Outlook Lift
- Positive Sentiment: Patent enforcement win: A Dutch court ordered Ceban Ziekenhuisfarmacie to stop selling an infringing compounded semaglutide nasal spray, remove product listings and provide supply-chain information. The ruling could help protect Novo’s semaglutide franchise from unauthorized competition in the Netherlands. Novo Nordisk wins Dutch court injunction
- Neutral Sentiment: Novo declared a dividend of 0.5786 per share, payable August 25 to shareholders of record August 17. The reported 254% yield appears inconsistent with the stated dividend and should be treated cautiously pending confirmation. Novo Nordisk dividend and insider transactions announcement
- Negative Sentiment: Pipeline and competitive concerns remain the main overhang: Investors focused on weaker-than-expected Wegovy pill sales, a setback for the next-generation obesity treatment CagriSema, U.S. pricing pressure and the widening commercial lead of Eli Lilly’s GLP-1 portfolio. These issues overshadowed the earnings beat and guidance increase. The divide between Eli Lilly and Novo Nordisk is widening
Novo Nordisk A/S Trading Up 3.1%
Novo Nordisk A/S (NYSE:NVO – Get Free Report) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The business had revenue of $11.98 billion during the quarter. On average, research analysts predict that Novo Nordisk A/S will post 3.39 earnings per share for the current fiscal year.
Novo Nordisk A/S Cuts Dividend
The business also recently announced a dividend, which will be paid on Tuesday, August 25th. Investors of record on Monday, August 17th will be paid a $0.5786 dividend. The ex-dividend date is Monday, August 17th. This represents a yield of 254.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 42.79%.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on NVO. BMO Capital Markets reiterated a “market perform” rating and issued a $47.00 price target on shares of Novo Nordisk A/S in a report on Thursday. Zacks Research lowered Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday. Finally, Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Five analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $65.81.
Get Our Latest Stock Analysis on Novo Nordisk A/S
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.
The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.
Read More
- Five stocks we like better than Novo Nordisk A/S
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
